DK0489072T3 - Behandling af kronisk inflammatoriske tilstande - Google Patents

Behandling af kronisk inflammatoriske tilstande

Info

Publication number
DK0489072T3
DK0489072T3 DK90912793.8T DK90912793T DK0489072T3 DK 0489072 T3 DK0489072 T3 DK 0489072T3 DK 90912793 T DK90912793 T DK 90912793T DK 0489072 T3 DK0489072 T3 DK 0489072T3
Authority
DK
Denmark
Prior art keywords
treatment
chronic inflammatory
inflammatory conditions
patient
abnormally high
Prior art date
Application number
DK90912793.8T
Other languages
Danish (da)
English (en)
Inventor
John Lawson Stanford
Graham Arthur William Rook
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of DK0489072T3 publication Critical patent/DK0489072T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Treatment Of Sludge (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK90912793.8T 1989-08-25 1990-08-24 Behandling af kronisk inflammatoriske tilstande DK0489072T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898919321A GB8919321D0 (en) 1989-08-25 1989-08-25 Treatment of chronic inflammatory conditions

Publications (1)

Publication Number Publication Date
DK0489072T3 true DK0489072T3 (da) 1996-04-15

Family

ID=10662094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90912793.8T DK0489072T3 (da) 1989-08-25 1990-08-24 Behandling af kronisk inflammatoriske tilstande

Country Status (13)

Country Link
US (1) US5833996A (de)
EP (1) EP0489072B1 (de)
JP (1) JP2987197B2 (de)
AT (1) ATE135588T1 (de)
AU (1) AU644813B2 (de)
CA (1) CA2065286C (de)
DE (1) DE69026094T2 (de)
DK (1) DK0489072T3 (de)
FI (1) FI920795A0 (de)
GB (2) GB8919321D0 (de)
NO (1) NO920722L (de)
WO (1) WO1991002542A1 (de)
ZA (1) ZA906753B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AUPO359396A0 (en) * 1996-11-13 1996-12-05 Amrad Operations Pty. Limited A method of treatment and pharmaceutical compositions useful for same
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU730548B2 (en) * 1996-12-18 2001-03-08 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the TH2 activity of the immune system
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
RU2135196C1 (ru) * 1996-12-19 1999-08-27 Научно-исследовательский институт по изучению лепры Способ иммунопрофилактики экспериментальной лепрозной инфекции
AR012304A1 (es) * 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
KR20060111731A (ko) 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
GB9723630D0 (en) * 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
RU2137137C1 (ru) * 1997-12-03 1999-09-10 Научно-исследовательский институт по изучению лепры Способ определения m.leprae у больных с регрессом заболевания
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
EP1044273A2 (de) * 1997-12-23 2000-10-18 Genesis Research & Development Corporation Limited Von mycobacterium vaccae abgeleitete zusammensetzungen und methoden für ihre verwendung
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
WO2001010221A1 (en) * 1999-08-06 2001-02-15 Corixa Corporation Vaccines for the treatment of autoimmune disease
JP2003519668A (ja) 2000-01-14 2003-06-24 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
DK1296711T3 (da) 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
GB0106987D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeuitic agent
ES2526822T3 (es) 2002-01-31 2015-01-15 Andromeda Bio Tech Ltd. Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2487198A1 (fr) * 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens

Also Published As

Publication number Publication date
GB2252044A (en) 1992-07-29
JP2987197B2 (ja) 1999-12-06
AU6289790A (en) 1991-04-03
US5833996A (en) 1998-11-10
CA2065286A1 (en) 1991-02-26
JPH05501870A (ja) 1993-04-08
FI920795A7 (fi) 1992-02-24
AU644813B2 (en) 1993-12-23
EP0489072A1 (de) 1992-06-10
DE69026094D1 (de) 1996-04-25
GB2252044B (en) 1993-09-22
ATE135588T1 (de) 1996-04-15
GB8919321D0 (en) 1989-10-11
GB9203904D0 (en) 1992-04-15
NO920722D0 (no) 1992-02-24
EP0489072B1 (de) 1996-03-20
FI920795A0 (fi) 1992-02-24
WO1991002542A1 (en) 1991-03-07
NO920722L (no) 1992-04-24
CA2065286C (en) 2000-05-16
DE69026094T2 (de) 1996-08-22
ZA906753B (en) 1991-06-26

Similar Documents

Publication Publication Date Title
DK0489072T3 (da) Behandling af kronisk inflammatoriske tilstande
ES2104731T3 (es) Micobacterium utilizado como adyuvante para antigenos.
NO20000413L (no) Karbamyloksyforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
DE69905368D1 (en) Oxydiertes thymosin beta 4
IT7823092A0 (it) Corpo di carbonio in forma di una placca, e procedimento per la sua fabbricazione.
TR199900656T2 (xx) �ndanonlar ile 262 ve 20S proteazomun engellenmesi.
FI914393A0 (fi) Anordning foer soenderdelning av konkrement i kroppen pao en patient.
ES514888A0 (es) Procedimiento para la fabricacion de briquetas de coque de alta resistencia.
WO2001051008A3 (en) Selective activation of a th1 or th2 lymphocyte regulated immune response
DK304485A (da) Faste laegemiddelpraeparater med dihydropyridiner samt fremstilling deraf
FR2348704A1 (fr) Procede de preparation d'un vaccin contre le virus de la rhinopneumonie equine et vaccin ainsi obtenu
DE68904382D1 (de) Schlagfesten kautschuk enthaltende schmelzklebstoffzusammensetzungen fuer die buchbinderei.
IT8984980A0 (it) Procedimento per la realizzazione di cingoli in gomma e cingolo cosi'.
IT9020020A0 (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
ES532286A0 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
IT7928015A0 (it) Derivato del paracetamol,procedimento per la sua preparazione e suo impiego nel campo terapeutico.
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
Tritsch et al. Adenosine deaminase activity during the growth cycle of T and B lymphoid cell lines
FI914160A0 (fi) Analysis och behandling av auto- immuniska sjukdomar.
Romagnani et al. Human Th1 and Th2 cells: Regulation of development and role in protection and disease
IE801737L (en) (20 s) 3ó-aminoacetamido-5ó-pregnan-20-ol
Bair et al. The diagnostic value of IgM to natural trisaccharide phenylpropionyl bovine serum albumin in leprosy patients: a preliminary report from Taiwan
JPS5427390A (en) Bedstead device
SU852657A1 (ru) Токоприемник
FUKATA et al. Soybean Production on the Drained Paddy Field by Farmer's Group IV. Systematic use on the paddy field